MDD
MCID: MJR011
MIFTS: 53

Major Depressive Disorder and Accelerated Response to Antidepressant Drug Treatment (MDD) malady

Categories: Genetic diseases, Mental diseases

Aliases & Classifications for Major Depressive Disorder and Accelerated Response to...

Aliases & Descriptions for Major Depressive Disorder and Accelerated Response to Antidepressant Drug Treatment:

Name: Major Depressive Disorder and Accelerated Response to Antidepressant Drug Treatment 54
Seasonal Affective Disorder 54 12 66 52 41 14 69
Major Depressive Disorder 38 66 29 13 69
Major Depressive Disorder 1 54 29 13 69
Major Depressive Disorder 2 54 29 13 69
Unipolar Depression 54 66 52 69
Winter Depression 12 69
Major Depressive Disorder, Response to Citalopram Therapy in 54
Depressive Disorder, Major 42
Mdd 66
Sad 66

Classifications:



External Ids:

OMIM 54 608516
Disease Ontology 12 DOID:0060167
MeSH 42 D003865

Summaries for Major Depressive Disorder and Accelerated Response to...

MedlinePlus : 41 some people experience a serious mood change during the winter months, when there is less natural sunlight. this condition is called seasonal affective disorder, or sad. sad is a type of depression. it usually lifts during spring and summer. not everyone with sad has the same symptoms. they include sad, anxious or "empty" feelings feelings of hopelessness and/or pessimism feelings of guilt, worthlessness or helplessness irritability, restlessness loss of interest or pleasure in activities you used to enjoy fatigue and decreased energy difficulty concentrating, remembering details and making decisions difficulty sleeping or oversleeping changes in weight thoughts of death or suicide sad may be effectively treated with light therapy. but nearly half of people with sad do not respond to light therapy alone. antidepressant medicines and talk therapy can reduce sad symptoms, either alone or combined with light therapy. nih: national institute of mental health

MalaCards based summary : Major Depressive Disorder and Accelerated Response to Antidepressant Drug Treatment, also known as seasonal affective disorder, is related to hypoglycemia and schizophrenia, and has symptoms including depressive symptoms An important gene associated with Major Depressive Disorder and Accelerated Response to Antidepressant Drug Treatment is HTR2A (5-Hydroxytryptamine Receptor 2A), and among its related pathways/superpathways are Peptide ligand-binding receptors and Circadian entrainment. The drugs Dopamine and Norepinephrine have been mentioned in the context of this disorder. Related phenotypes are behavior/neurological and homeostasis/metabolism

Disease Ontology : 12 A mental depression that involves presentation of depressive symptoms only during a specific season of the year.

UniProtKB/Swiss-Prot : 66 Major depressive disorder: A common psychiatric disorder. It is a complex trait characterized by one or more major depressive episodes without a history of manic, mixed, or hypomanic episodes. A major depressive episode is characterized by at least 2 weeks during which there is a new onset or clear worsening of either depressed mood or loss of interest or pleasure in nearly all activities. Four additional symptoms must also be present including changes in appetite, weight, sleep, and psychomotor activity; decreased energy; feelings of worthlessness or guilt; difficulty thinking, concentrating, or making decisions; or recurrent thoughts of death or suicidal ideation, plans, or attempts. The episode must be accompanied by distress or impairment in social, occupational, or other important areas of functioning.

Description from OMIM: 608516

Related Diseases for Major Depressive Disorder and Accelerated Response to...

Diseases related to Major Depressive Disorder and Accelerated Response to Antidepressant Drug Treatment via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 84)
id Related Disease Score Top Affiliating Genes
1 hypoglycemia 29.7 CRH DRD3 SLC6A4
2 schizophrenia 28.6 DRD3 DRD4 HTR1A HTR2A HTR2C HTR7
3 mal de debarquement 11.7
4 sudden arrhythmia death syndrome 11.4
5 endogenous depression 11.3
6 polyneuropathy 10.3 HTR1A HTR2A
7 intrahepatic gall duct cancer 10.3 HTR2A SLC6A4 TPH2
8 antisocial personality disorder 10.2 HTR1A HTR2A
9 colorectal adenocarcinoma 10.2 DRD4 SLC6A4 TPH2
10 hepatitis b reinfection following liver transplantation 10.2 HTR1A HTR2A SLC6A4
11 aryepiglottic fold cancer 10.2 HTR1A HTR2A
12 hereditary multiple exostoses 10.2 CRH FKBP5 HTR2A SLC6A4
13 bipolar disorder 10.2
14 anodontia 10.2 HTR1A HTR2C SLC6A4
15 nephronophthisis 13 10.2 HTR2A SLC6A4
16 carotid stenosis 10.2 DRD4 SLC6A4 TPH1
17 lichen disease 10.2 CRH HTR1A HTR2A SLC6A4
18 postencephalitic parkinson disease 10.2 HTR1A HTR2A SLC6A4 TPH1
19 waardenburg's syndrome 10.1 HTR1A HTR2A HTR2C SLC6A4
20 schizoid personality disorder 10.1 DRD3 SLC6A4
21 allergic hypersensitivity disease 10.1 HTR1A HTR2A HTR7
22 vascular cancer 10.1 HTR1A HTR2A HTR7
23 pyromania 10.1 DRD3 DRD4 HTR2A SLC6A4
24 hypoglycemic coma 10.1 CRH HTR1A HTR2A SLC6A4 TPH1
25 cytomegalic congenital adrenal hypoplasia 10.1 DRD3 DRD4 HTR2A SLC6A4
26 atrial fibrillation, familial, 10 10.1 HTR1A HTR2A SLC6A4 TPH1 TPH2
27 bartter disease 10.1 HTR2A HTR7 SLC6A4 TPH2
28 hypereosinophilic syndrome 10.1 DRD3 DRD4 SLC6A4
29 deafness, autosomal recessive 20 10.0 CRH HTR7 SLC6A4 TPH1
30 renpenning syndrome 10.0 HTR1A HTR7 SLC6A4 TPH1
31 tuberculous peritonitis 10.0 CRH HTR7 SLC6A4 TPH1
32 neurogenic bladder 10.0 GATA3 HTR2A HTR7 SLC6A4
33 fechtner syndrome 10.0 CRH HTR1A HTR2A SLC6A4 TPH1 TPH2
34 conjunctival pigmentation 10.0 CRH GATA3 HTR7 SLC6A4
35 tinea pedis 10.0 GATA3 HTR1A HTR7 SLC6A4
36 primary angle-closure glaucoma 10.0 HTR1A HTR2A HTR2C PER3 SLC6A4
37 paraphilia disorder 10.0 DRD3 DRD4 HTR2A SLC6A4 TPH2
38 multiple personality disorder 10.0 HTR1A HTR2A HTR2C SLC6A4 TPH1 TPH2
39 autism spectrum disorder 10.0 DRD4 HTR7 SLC6A4
40 dry eye syndrome 9.9 HTR1A HTR2A HTR2C HTR7 SLC6A4
41 abnormal pupillary function 9.9 HTR1A HTR7
42 hemolytic anemia, cd59-mediated, with or without immune-mediated polyneuropathy 9.9 CRH HTR2A PRL SLC6A4
43 chronic eosinophilic pneumonia 9.9 CRH HTR1A PRL SLC6A4
44 brain glioblastoma multiforme 9.9 DRD3 HTR1A HTR2A SLC6A4 TPH1 TPH2
45 thyroiditis 9.9
46 parotid gland cancer 9.9 HCRTR1 HTR2A SLC18A2 TPH1
47 rectosigmoid junction neoplasm 9.9 DRD4 HTR7 SLC18A2 TPH2
48 transmitted_by 9.9 DRD3 PRL SLC6A4
49 bipolar i disorder 9.9
50 anxiety disorder 9.9

Graphical network of the top 20 diseases related to Major Depressive Disorder and Accelerated Response to Antidepressant Drug Treatment:



Diseases related to Major Depressive Disorder and Accelerated Response to Antidepressant Drug Treatment

Symptoms & Phenotypes for Major Depressive Disorder and Accelerated Response to...

Clinical features from OMIM:

608516

UMLS symptoms related to Major Depressive Disorder and Accelerated Response to Antidepressant Drug Treatment:


depressive symptoms

MGI Mouse Phenotypes related to Major Depressive Disorder and Accelerated Response to Antidepressant Drug Treatment:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.3 PER3 PRL SLC18A2 SLC6A4 TPH1 TPH2
2 homeostasis/metabolism MP:0005376 10.13 HTR7 PER2 PRL SLC18A2 SLC6A4 TPH1
3 cardiovascular system MP:0005385 9.97 PER2 SLC18A2 SLC6A4 TPH1 TPH2 CRY2
4 adipose tissue MP:0005375 9.95 CRH CRY2 DRD3 GATA3 HTR2C TPH1
5 integument MP:0010771 9.85 CRH CRY2 GATA3 HTR2C HTR7 PER2
6 muscle MP:0005369 9.5 CRY2 GATA3 HTR2A HTR2C SLC18A2 SLC6A4
7 nervous system MP:0003631 9.5 CRH CRY2 DRD3 DRD4 GATA3 HCRTR1

Drugs & Therapeutics for Major Depressive Disorder and Accelerated Response to...

Drugs for Major Depressive Disorder and Accelerated Response to Antidepressant Drug Treatment (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 760)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
2
Norepinephrine Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 51-41-2 439260
3
Fluoxetine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 54910-89-3 3386
4
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
5
Citalopram Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 59729-33-8 2771
6
Fluvoxamine Approved, Investigational Phase 4 54739-18-3 3404 5324346
7
Paroxetine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61869-08-7 43815
8
Sertraline Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 79617-96-2 68617
9
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 75614-87-8, 51-45-6 774
10
Mianserin Approved Phase 4,Phase 3,Phase 2,Early Phase 1 24219-97-4 4184
11
Mirtazapine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 85650-52-8, 61337-67-5 4205
12
Bupropion Approved Phase 4,Phase 3,Phase 2,Phase 1 34841-39-9, 34911-55-2 444
13
Trazodone Approved, Investigational Phase 4,Phase 3 19794-93-5 5533
14
Reboxetine Approved, Investigational Phase 4,Phase 2 98769-81-4, 71620-89-8 123628 65856
15
Eszopiclone Approved Phase 4,Phase 3,Phase 2 138729-47-2 969472
16
Buspirone Approved, Investigational Phase 4,Phase 2 36505-84-7 2477
17
Acetylcholine Approved Phase 4,Phase 2 51-84-3 187
18
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1 64-17-5 702
19
Amitriptyline Approved Phase 4,Phase 3,Phase 2 50-48-6 2160
20
Nortriptyline Approved Phase 4,Phase 2,Phase 1 72-69-5 4543
21
Perphenazine Approved Phase 4,Phase 3,Phase 2 58-39-9 4748
22
Trimipramine Approved Phase 4 739-71-9 5584 4055
23
Ropinirole Approved, Investigational Phase 4,Phase 3 91374-20-8, 91374-21-9 5095 497540
24
Ketamine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 6740-88-1 3821
25
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
26
Remifentanil Approved Phase 4,Phase 2,Phase 3 132875-61-7 60815
27
Milnacipran Approved Phase 4,Phase 3,Phase 2 92623-85-3 65833
28
Tranylcypromine Approved Phase 4,Phase 1,Phase 2,Early Phase 1 155-09-9 441233
29
Imipramine Approved Phase 4 50-49-7 3696
30
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
31
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 2,Phase 1 76631-46-4, 113775-47-6 68602 5311068 56032
32
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Phase 2 51-43-4 5816
33
Midazolam Approved, Illicit Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 59467-70-8 4192
34
Methylphenidate Approved, Investigational Phase 4,Phase 3,Phase 2 113-45-1 4158
35
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
36 Moxonidine Approved Phase 4 75438-57-2 4810
37
Risperidone Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 106266-06-2 5073
38
Topiramate Approved Phase 4,Phase 3 97240-79-4 5284627
39
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
40
Morphine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 57-27-2 5288826
41
Ropivacaine Approved Phase 4,Phase 2,Phase 3 84057-95-4 71273 175805
42
Riluzole Approved, Investigational Phase 4,Phase 2,Phase 1 1744-22-5 5070
43
Tianeptine Approved Phase 4,Phase 3 66981-73-5, 26638-66-4, 72797-41-2 3075702 68870
44
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 132539-06-1 4585
45
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 2 129722-12-9 60795
46
Memantine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 19982-08-2 4054
47
Benzocaine Approved Phase 4,Phase 3,Phase 2,Phase 1 1994-09-7, 94-09-7 2337
48
Armodafinil Approved, Investigational Phase 4,Phase 3,Phase 2 112111-43-0
49
Modafinil Approved, Investigational Phase 4,Phase 3,Phase 2 68693-11-8 4236
50
Nicotine Approved Phase 4,Phase 3,Phase 2,Phase 1 54-11-5 942 89594

Interventional clinical trials:

(show top 50) (show all 3135)
id Name Status NCT ID Phase
1 Inflammatory Markers and Cognitive Function in Major Depression Unknown status NCT01391221 Phase 4
2 Role of Inflammation Factors and Insulin Resistance in Major Depressive Disorder Unknown status NCT01699490 Phase 4
3 Magnetic Resonance Imaging Study of Cognitive-Behavior Therapy for Major Depressive Disorder Unknown status NCT01460212 Phase 4
4 Hippocampal Volume in Young Patients With Major Depression Before and After Combined Antidepressive Therapy Unknown status NCT00150839 Phase 4
5 Algorithm Guided Treatment Strategies for Major Depressive Disorder Unknown status NCT01764867 Phase 4
6 Major Depressive Disorder - Understanding The Link Between The Brain And The Heart Unknown status NCT01568307 Phase 4
7 Duloxetine for Major Depression in Peri-/Postmenopausal Women Unknown status NCT00889369 Phase 4
8 Cardiovascular Effects of Agomelatine and Escitalopram in Patients With Major Depressive Disorder (MDD) Unknown status NCT01483053 Phase 4
9 Effect of Partial Sleep Deprivation on Cognition and Cytokines in Individuals With Major Depression Unknown status NCT00291239 Phase 4
10 Prediction of Antidepressant Treatment Response Using Machine Learning Classification Analysis Unknown status NCT02330679 Phase 4
11 Effect of Escitalopram vs. Reboxetine on Gastro-intestinal Sensitivity of Patients With Major Depressive Disorder Unknown status NCT00209807 Phase 4
12 Escitalopram and Sleep Architecture in Patients With Major Depressive Disorder Unknown status NCT00442481 Phase 4
13 Efficacy Study of Escitalopram for Depression in Patients With Diabetes Unknown status NCT00650897 Phase 4
14 Brain Mechanisms and Targeting Insomnia in Major Depression Unknown status NCT00628914 Phase 4
15 Effectiveness of Repetitive Transcranial Magnetic Stimulation in Depressed Patients Unknown status NCT02213016 Phase 4
16 Randomized,Controlled and Open-label Study of Buspirone add-on Treatment in Patients With Major Depression Disorder Unknown status NCT02273154 Phase 4
17 Effect of Antidepressants on White Matter Structure Unknown status NCT01492621 Phase 4
18 Efficacy Study of Botox for Depression Unknown status NCT01556971 Phase 4
19 Clinical Pharmacogenomics of Antidepressant Response Unknown status NCT00269334 Phase 4
20 The Effect of Quetiapine XR in Depressive Patients Showing Aberrant N100 Amplitude Slope Unknown status NCT01357967 Phase 4
21 Antidepressant Maintenance in Traumatic Brain Injury Unknown status NCT00162916 Phase 4
22 Estrogen and Perimenopausal Depression Unknown status NCT00229450 Phase 4
23 Fluoxetine and Bupropion to Treat Patients With Depression and Alcoholism Unknown status NCT00449007 Phase 4
24 Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene Unknown status NCT02237937 Phase 4
25 Benefits of Switching Antidepressants Following Early Nonresponse Unknown status NCT00519012 Phase 4
26 Pharmacogenomics Studies of Antidepressants Unknown status NCT01204086 Phase 4
27 A Comprehensive Intervention for Diabetes and Comorbid Depression in Primary Care Unknown status NCT00939250 Phase 4
28 A Placebo Controlled Trial of the Dopamine D-2 Receptor Agonist Ropinirole in Treatment of 60 Patients With Refractory Bipolar Depression. Unknown status NCT00335205 Phase 4
29 Desvenlafaxine vs. Placebo Treatment of Chronic Depression Unknown status NCT01537068 Phase 4
30 Effect of the Addition of Ketamine to Sevoflurane Anesthesia in Electroconvulsive Therapy Unknown status NCT02267980 Phase 4
31 The Effects of Remifentanil on Attenuating the Hemodynamic Responses After Electroconvulsive Therapy Unknown status NCT02271555 Phase 4
32 Depression Care Management for Depressed Elders in China Primary Care Unknown status NCT01287494 Phase 4
33 Study to Evaluate the Efficacy of Milnacipran in the Treatment of Pain Due to Osteoarthritis Unknown status NCT01329406 Phase 4
34 Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in Polycystic Ovary Syndrome (PCOS) Patients Unknown status NCT01246310 Phase 4
35 Reboxetine Treatment in Depressed Children and Adolescents an 8-Week, Open Study Unknown status NCT00426946 Phase 4
36 Tranylcypromine Treatment of Bipolar Depression Unknown status NCT01430455 Phase 4
37 Imipramine and Pregabalin Combination in Painful Polyneuropathy Unknown status NCT01047488 Phase 4
38 Agomelatine Treatment of Depression in Schizophrenia (AGOPSYCH) Unknown status NCT01822418 Phase 4
39 The Effect of Duloxetine on Interoceptive Awareness Unknown status NCT00337012 Phase 4
40 Safety Evaluation of Dexmedetomidine for EBUS-TBNA Unknown status NCT01381627 Phase 4
41 A Study to Evaluate the Efficacy and Safety of Flexible Dose of Quetiapine Fumarate (Seroquel) Switching From Other Drugs in the Treatment of Acute Manic Patients With Bipolar Disorder Unknown status NCT00837343 Phase 4
42 Methylphenidate in Healthy Young Adults Unknown status NCT00815841 Phase 4
43 Efficacy of Omega-3 Fatty Acids on Borderline Personality Disorder Unknown status NCT00437099 Phase 4
44 The Effect of Moxonidine on Blood Pressure and Regression of Early Target Organ Damage in Young Subjects With Abdominal Obesity and Hypertension Unknown status NCT01360710 Phase 4
45 Exacerbation Prevention GOLD IV COPD With Non Invasive Mechanical Ventilation Unknown status NCT01481727 Phase 4
46 Methylphenidate vs. Risperidone for the Treatment of Children and Adolescents With ADHD and Disruptive Disorders Unknown status NCT02063945 Phase 4
47 Topiramate in the Treatment of Pathological Gambling Unknown status NCT00245583 Phase 4
48 Analgesia After Total Knee Arthroplasty Unknown status NCT00869037 Phase 4
49 Efficacy and Tolerability of Escitalopram and Duloxetine in Outpatients With Major Depressive Disorder Completed NCT01148472 Phase 4
50 An Efficacy and Safety Study of Escitalopram Long-Term Treatment in Major Depressive Disorder With Associated Anxiety Symptoms Completed NCT01814098 Phase 4

Search NIH Clinical Center for Major Depressive Disorder and Accelerated Response to Antidepressant Drug Treatment

Cochrane evidence based reviews: depressive disorder, major

Genetic Tests for Major Depressive Disorder and Accelerated Response to...

Genetic tests related to Major Depressive Disorder and Accelerated Response to Antidepressant Drug Treatment:

id Genetic test Affiliating Genes
1 Major Depressive Disorder 29
2 Major Depressive Disorder 1 29
3 Major Depressive Disorder 2 29

Anatomical Context for Major Depressive Disorder and Accelerated Response to...

Publications for Major Depressive Disorder and Accelerated Response to...

Variations for Major Depressive Disorder and Accelerated Response to...

Expression for Major Depressive Disorder and Accelerated Response to...

Search GEO for disease gene expression data for Major Depressive Disorder and Accelerated Response to Antidepressant Drug Treatment.

Pathways for Major Depressive Disorder and Accelerated Response to...

Pathways related to Major Depressive Disorder and Accelerated Response to Antidepressant Drug Treatment according to GeneCards Suite gene sharing:

(show all 13)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.38 CRH DRD3 DRD4 HCRTR1 HTR1A HTR2A
2
Show member pathways
12.54 DRD3 DRD4 PER2 PER3 SLC18A2
3 12.01 GATA3 HTR1A HTR2A SLC6A4 TPH1 TPH2
5 11.81 HTR1A HTR2A HTR2C HTR7 SLC18A2 SLC6A4
6
Show member pathways
11.79 DRD3 DRD4 HTR1A HTR2A HTR2C HTR7
7
Show member pathways
11.69 DRD3 DRD4 SLC18A2
8 11.68 DRD3 DRD4 HTR2A HTR7
9 11.58 FKBP5 GATA3 PRL
10
Show member pathways
11.24 CRY2 PER2 PER3
11 11.15 CRY2 PER2 PER3
12 10.83 HTR2A HTR2C
13 10.67 HTR1A HTR2A HTR2C HTR7 SLC18A2 SLC6A4

GO Terms for Major Depressive Disorder and Accelerated Response to...

Cellular components related to Major Depressive Disorder and Accelerated Response to Antidepressant Drug Treatment according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.28 DRD3 DRD4 HCRTR1 HTR1A HTR2A HTR2C

Biological processes related to Major Depressive Disorder and Accelerated Response to Antidepressant Drug Treatment according to GeneCards Suite gene sharing:

(show all 44)
id Name GO ID Score Top Affiliating Genes
1 rhythmic process GO:0048511 9.88 CRY2 DRD4 PER2 PER3
2 response to ethanol GO:0045471 9.88 CRH DRD3 GATA3 PRL
3 locomotory behavior GO:0007626 9.85 DRD3 HTR2C SLC18A2
4 response to estrogen GO:0043627 9.82 CRH GATA3 TPH2
5 cellular calcium ion homeostasis GO:0006874 9.81 DRD3 DRD4 HTR2A HTR2C
6 social behavior GO:0035176 9.8 DRD3 DRD4 SLC6A4
7 regulation of circadian rhythm GO:0042752 9.79 CRY2 DRD4 PER2
8 positive regulation of fat cell differentiation GO:0045600 9.79 HTR2A HTR2C TPH1
9 behavioral fear response GO:0001662 9.71 DRD4 HTR1A HTR2C
10 circadian regulation of gene expression GO:0032922 9.71 CRY2 DRD3 PER2 PER3
11 response to amphetamine GO:0001975 9.7 DRD3 DRD4 SLC18A2
12 smooth muscle contraction GO:0006939 9.69 HTR2A HTR7
13 dopamine receptor signaling pathway GO:0007212 9.69 DRD3 DRD4
14 synaptic transmission, dopaminergic GO:0001963 9.69 CRH DRD3
15 positive regulation of kinase activity GO:0033674 9.68 DRD4 HTR2A
16 dopamine metabolic process GO:0042417 9.68 DRD3 DRD4
17 negative regulation of protein secretion GO:0050709 9.68 DRD3 DRD4
18 parturition GO:0007567 9.67 CRH PRL
19 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.67 DRD3 DRD4
20 regulation of dopamine metabolic process GO:0042053 9.66 DRD4 HTR1A
21 regulation of behavior GO:0050795 9.66 HTR1A HTR2A
22 negative regulation of circadian rhythm GO:0042754 9.65 CRY2 PER2
23 monoamine transport GO:0015844 9.65 SLC18A2 SLC6A4
24 aromatic amino acid family metabolic process GO:0009072 9.64 TPH1 TPH2
25 regulation of hormone secretion GO:0046883 9.63 HTR1A HTR2A
26 behavioral response to cocaine GO:0048148 9.63 DRD3 DRD4 HTR2A
27 chemical synaptic transmission GO:0007268 9.63 CRH HCRTR1 HTR2A HTR2C HTR7 SLC18A2
28 indolalkylamine biosynthetic process GO:0046219 9.61 TPH1 TPH2
29 vasoconstriction GO:0042310 9.61 HTR1A HTR7 SLC6A4
30 adenylate cyclase-inhibiting serotonin receptor signaling pathway GO:0007198 9.6 HTR1A HTR7
31 positive regulation of phosphatidylinositol biosynthetic process GO:0010513 9.59 HTR2A HTR2C
32 serotonin transport GO:0006837 9.57 SLC18A2 SLC6A4
33 serotonin biosynthetic process GO:0042427 9.56 TPH1 TPH2
34 response to histamine GO:0034776 9.55 DRD3 DRD4
35 behavior GO:0007610 9.54 HTR1A HTR2A HTR2C
36 regulation of circadian sleep/wake cycle, sleep GO:0045187 9.5 DRD3 HCRTR1 PER3
37 response to drug GO:0042493 9.5 CRH DRD3 GATA3 HTR2A HTR2C PRL
38 phospholipase C-activating serotonin receptor signaling pathway GO:0007208 9.49 HTR2A HTR2C
39 regulation of serotonin secretion GO:0014062 9.48 CRH HTR1A
40 serotonin receptor signaling pathway GO:0007210 9.43 HTR1A HTR2A HTR2C
41 circadian rhythm GO:0007623 9.23 CRY2 HTR7 PER2 PER3 PRL SLC6A4
42 signal transduction GO:0007165 10.29 CRH DRD3 DRD4 GATA3 HCRTR1 HTR1A
43 G-protein coupled receptor signaling pathway GO:0007186 10.18 DRD3 DRD4 HCRTR1 HTR1A HTR2A HTR2C
44 positive regulation of cell proliferation GO:0008284 10.07 CRH DRD3 HTR1A HTR2A PRL

Molecular functions related to Major Depressive Disorder and Accelerated Response to Antidepressant Drug Treatment according to GeneCards Suite gene sharing:

(show all 16)
id Name GO ID Score Top Affiliating Genes
1 G-protein coupled receptor activity GO:0004930 9.98 DRD3 DRD4 HCRTR1 HTR1A HTR2A HTR2C
2 signal transducer activity GO:0004871 9.93 DRD3 DRD4 HTR1A HTR2A HTR2C
3 transcription regulatory region sequence-specific DNA binding GO:0000976 9.67 CRY2 GATA3 PER2
4 transcription factor activity, transcription factor binding GO:0000989 9.56 CRY2 PER2
5 drug binding GO:0008144 9.56 DRD3 DRD4 HTR2A HTR2C
6 dopamine binding GO:0035240 9.55 DRD3 DRD4
7 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.52 DRD3 DRD4
8 monoamine transmembrane transporter activity GO:0008504 9.51 SLC18A2 SLC6A4
9 dopamine neurotransmitter receptor activity GO:0004952 9.48 DRD3 DRD4
10 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced pteridine as one donor, and incorporation of one atom of oxygen GO:0016714 9.46 TPH1 TPH2
11 G-protein coupled serotonin receptor activity GO:0004993 9.46 HTR1A HTR2A HTR2C HTR7
12 serotonin transmembrane transporter activity GO:0015222 9.4 SLC18A2 SLC6A4
13 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding GO:0071886 9.37 HTR2A HTR2C
14 tryptophan 5-monooxygenase activity GO:0004510 9.32 TPH1 TPH2
15 neurotransmitter receptor activity GO:0030594 9.26 HTR1A HTR2A HTR2C HTR7
16 serotonin binding GO:0051378 8.92 HTR1A HTR2A HTR2C HTR7

Sources for Major Depressive Disorder and Accelerated Response to...

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....